Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

David D. Stenehjem, Andrew W. Hahn, David M. Gill, Daniel Albertson, Banumathy Gowrishankar, Joseph Merriman, Archan A. Agarwal, Venkata Thodima, Erik B. Harrington, Trang H. Au, Benjamin L. Maughan, Jane Houldsworth, and Sumanta K. Pal

Abstract

Background

First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of response to therapy are needed. Here, we aim to identify tumor-based genomic markers of response to VEGF TT to optimize treatment selection.

Methods

From an institutional database, primary tumor tissue was obtained from 79 patients with clear cell mRCC, and targeted sequencing was performed. Clinical outcomes were obtained retrospectively. Progression-free survival (PFS) on first-line VEGF TT was correlated to genomic alterations (GAs) using Kaplan-Meier methodology and Cox proportional hazard models. A composite model of significant GAs predicting PFS in the first-line setting was developed.

Results

Absence of VHL mutation was associated with inferior PFS on first-line VEGF TT. A trend for inferior PFS was observed with GAs in TP53 and FLT1 C/C variant. A composite model of these 3 GAs was associated with inferior PFS in a dose-dependent manner.
Conclusion

In mRCC, a composite model of TP53 mutation, wild type VHL, and FLT1 C/C variant strongly predicted PFS on first-line VEGF TT in a dose-dependent manner. These findings require external validation.

Introduction

Renal cell carcinoma (RCC) is the sixth highest cause of cancer-related mortality [1]. 25–33% of patients will present with metastatic renal cell carcinoma (mRCC), and an additional 40% of patients who present with localized disease will develop metastases [2, 3]. First-line treatment for mRCC is rapidly evolving as therapies targeting vascular endothelial growth factor (VEGF), MET, mechanistic target of rapamycin (mTOR), and immune checkpoints are currently used. First-line treatments currently approved by the Food and Drug Administration (FDA) include sunitinib, pazopanib, bevacizumab with interferon alpha, sorafenib, temsirolimus, cabozantinib, and nivolumab plus ipilimumab [4]. More changes to first-line treatment are expected to arrive in the near future. Novel combinations of checkpoint inhibitors and VEGF TT (axitinib plus avelumab or pembrolizumab, and bevacizumab plus atezolizumab) are in advanced phases of development and at least some are expected to garner approval in the first-line setting [5]. Despite the availability of so many agents, limited data exists comparing these first-line agents. Thus, selection of a first-line agent is primarily based on comparisons of clinical trial data or anecdotal experiences of individual physicians.

The prognostic risk models, such as International Metastatic Renal Cell Carcinoma Consortium (IMDC), are also useful prognostic tools for mRCC that utilize readily available clinical factors, such as hemoglobin, platelet count, and Karnofsky performance scale, to indirectly reflect the underlying biology of mRCC. These risk models have been validated to predict overall survival prior to different lines of therapy and different classes of drugs [6, 7]. Furthermore, some treatments are only approved for specific IMDC prognostic groups, such as nivolumab plus ipilimumab or temsirolimus. However, they aren’t validated to predict which first-line agent a patient would best respond to among the many available. Genetic biomarkers predictive of differential benefit to first-line treatments are an ideal way to further improve outcomes for mRCC. However, no such biomarkers are routinely used in clinical practice. The purpose of this study was to identify predictive genomic markers of response to VEGF targeted therapy in the first-line setting for mRCC.

Results

Patient characteristics and frequency of GAs

A total of 79 patients with mRCC who were treated with first-line VEGF TT and had primary tumor tissue available were included. Patient baseline characteristics are shown in Table 1. For IMDC risk stratification, 60% of patients were intermediate risk and 31% had poor risk disease. The most commonly used first-line treatments were sunitinib (77%) and pazopanib (11%). 30% of patients were previously treated with high-dose interleukin-2, and no patients were previously treated with an immune checkpoint inhibitor. The most common sites of metastatic disease were lung, lymph nodes, bone, and liver. In all patients, GAs in VHL (75%) were most common, followed by PBRM1 (35%), SETD2 (23%), and BAP1 (25%), (Table 2, Fig 1). In IMDC intermediate risk patients, VHL (72%), PBRM1 (40%), SETD2 (28%), and KDM5C (26%) were the most prevalent GAs.

Competing interests: NA has been a consultant for Pfizer, Exelixis, Merck, Argos, EMD Serono, and Eisai, and has received research funding from Pfizer, EMD Serono, and Bayer. SKP is a consultant for Exelixis, BMS, GSK, Novartis, Pfizer, Astellas, and Genentech, and receives honoraria from Genentech. BG, VT, and JH receive salary support from Cancer Genetics, Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Correlation of GAs and progression-free survival on first-line VEGF TT in all patients

*VHL* mutations were associated with improved PFS (HR 0.41, 95% CI 0.21–0.82; p = 0.007) *(Table 3, Fig 2A).* *TP53* mutations demonstrated a trend towards shorter PFS in the first-line setting (3.9 vs. 11.3 months, HR 2.61, 95% CI 0.78–6.57; p = 0.059), *(Table 3, Fig 2C).* *PBRM1, SETD2, BAP1, KDM5C, MAGEC1,* and *mTOR* mutations were not associated with significant differences in PFS compared to wild type. A trend for inferior PFS was observed in patients with the *FLT1 C/C* variant (5.2 months) compared to the A/A variant (9.7 months, p = 0.074) and the A/C variant (12 months, p = 0.17) respectively *(Table 3, Fig 2E).* After correction for IMDC prognostic criteria in the Cox proportional hazard models, *VHL* mutations remained a significant predictor of improved PFS in the first-line setting (HR 0.45, 95% CI 0.23–0.89; p = 0.022).

Developing a composite model of predictive GAs for response to first line VEGF TT for all patients

Since *VHL* wild type, mutated *TP53,* and *FLT1 C/C* SNP were associated with a trend towards shorter PFS *(Table 3),* we hypothesized that a composite model utilizing these 3 GAs would serve as a stronger predictive biomarker for response to first-line VEGF TT in clear cell mRCC. The composite model was associated with inferior PFS in a dose-dependent manner.

**Table 1. Baseline patient characteristics.**

| All Patients | N = 79 |
|--------------|-------|
| **Age, y (%)** |       |
| Median (IQR) | 61 (55–70) |
| **Gender, n (%)** |       |
| Male | 56 (71) |
| **Race, n (%)** |       |
| White | 70 (89) |
| Hispanic | 3 (4) |
| Other | 6 (8) |
| **IMDC risk criteria, n (%)** |       |
| Favorable | 7 (9) |
| Intermediate | 47 (60) |
| Poor | 24 (31) |
| **Prior cytokine-based immunotherapy, n (%)** |       |
| Yes | 24 (30) |
| **First line treatment, n (%)** |       |
| Sunitinib | 61 (77) |
| Sorafenib | 6 (8) |
| Pazopanib | 9 (11) |
| Bevacizumab | 3 (4) |
| **Sites of Metastases, n (%)** |       |
| Lung | 56 (71) |
| Lymph nodes | 36 (46) |
| Bone | 29 (37) |
| Liver | 17 (22) |
| Peritoneum | 2 (3) |
| Brain | 8 (10) |
| Other | 39 (49) |

https://doi.org/10.1371/journal.pone.0210415.t001
Patients with 2 or 3 GAs had PFS of 3.9 months, whereas those harboring 1 GA had PFS of 9.1 months (HR 3.83, 95% CI 1.18–10.88, p = 0.005). In comparison to the PFS of 3.9 months seen in those with 2 or 3 GAs, patients with no GAs had superior PFS at 14.5 months (HR 6.83, 95% CI 2.17–18.26, p = 0.01). When controlling for IMDC risk category in a Cox proportional hazard model, the composite model was still predictive of inferior PFS in a dose-dependent manner (Table 4). Finally, presence of 1 or more GAs in the composite model was prognostic for inferior overall survival (OS) (Table 4).

**Discussion**

Numerous targeted therapies are available for first-line treatment of mRCC, and more are expected to receive approval in the near future. Yet, limited data on genetic biomarkers exist, and no biomarkers are currently used in the clinic to guide treatment selection in mRCC. In our study, patients with wild type VHL had shorter PFS in response to VEGF targeted therapies compared to those with GAs in VHL. Furthermore, GAs in TP53 and the FLT1 C/C SNP were associated with a trend towards shorter PFS. A composite model using wild type VHL, mutated TP53, and FLT1 C/C was predictive of response to first-line VEGF targeted therapies.

![Fig 1. Somatic variants in 79 clear cell mRCC tumors.](https://doi.org/10.1371/journal.pone.0210415.g001)
in a dose-dependent manner. Since the composite model was predictive of inferior PFS when controlling for IMDC risk group, it could be used to complement a clinical prognostication tool, such as the IMDC risk score.

Comprehensive characterization of stage I-IV RCC by The Cancer Genome Atlas (TCGA) demonstrated that the 8 most frequent mutations in RCC are: \textit{VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, MTOR, and TP53} [8]. Biallelic inactivation of \textit{VHL} is common in RCC. \textit{VHL} encodes a protein that ubiquitinates HIF to mark it for proteasome degradation.

| Table 3. Median progression-free survival by gene variants in all patients and in IMDC intermediate risk patients. |
|---------------------------------------------------------------|
| **Gene** | **All Patients** | | **IMDC Intermediate risk criteria patients** | |
| | n = 79 | PFS (mos) | HR (95% CI) | Log-Rank | n = 47 | PFS (mos) | HR (95% CI) | Log-Rank |
| VHL | Mutation | 60 | 14.5 | 0.41 (0.21–0.82) | **0.0070** | 34 | 11.3 | 0.43 (0.20–0.97) | **0.029** |
| | Wildtype | 19 | 7.0 | | | 13 | 6.0 | | |
| PBRM1 | Mutation | 28 | 14.9 | 0.77 (0.42–1.40) | 0.40 | 19 | 12.0 | 0.59 (0.27–1.21) | **0.15** |
| | Wildtype | 51 | 9.2 | | | 28 | 9.1 | | |
| SETD2 | Mutation | 18 | 13.5 | 1.01 (0.47–1.96) | 0.98 | 13 | 13.5 | 0.79 (0.33–1.71) | **0.57** |
| | Wildtype | 61 | 9.7 | | | 34 | 9.5 | | |
| BAP1 | Mutation | 20 | 8.2 | 1.13 (0.59–2.08) | 0.69 | 10 | 9.1 | 1.13 (0.47–2.45) | **0.76** |
| | Wildtype | 59 | 11.3 | | | 37 | 9.7 | | |
| KDM5C | Mutation | 18 | 11.4 | 0.98 (0.47–1.87) | 0.95 | 12 | 11.4 | 0.91 (0.36–2.01) | **0.82** |
| | Wildtype | 61 | 9.7 | | | 35 | 9.2 | | |
| MAGEC1 | Mutation | 13 | 7 | 0.80 (0.30–1.76) | 0.60 | 6 | 6.7 | 0.83 (0.24–2.14) | **0.72** |
| | Wildtype | 66 | 10.8 | | | 41 | 9.7 | | |
| mTOR | Mutation | 12 | 7.3 | 1.80 (0.84–3.51) | 0.10 | 7 | 9.2 | 1.12 (0.37–2.73) | **0.82** |
| | Wildtype | 67 | 11.4 | | | 40 | 9.7 | | |
| ROS1 | Mutation | 7 | 7.7 | 1.17 (0.40–2.70) | 0.71 | 5 | 7.3 | 1.73 (0.51–4.50) | **0.82** |
| | Wildtype | 72 | 10.8 | | | 42 | 9.7 | | |
| TP53 | Mutation | 5 | 3.9 | 2.61 (0.78–6.57) | 0.059 | 3 | 3.9 | 4.73 (1.07–15.01) | **0.007** |
| | Wildtype | 74 | 11.3 | | | 44 | 9.7 | | |
| FLTI (rs9582036) | A/A | 46 | 9.7 | A/A vs A/C: 0.71 (0.38–1.36) | 0.29 | 26 | 9.5 | A/A vs A/C: 0.92 (0.46–2.46) | **0.81** |
| | A/C | 26 | 12 | A/C vs C/C: 0.54 (0.21–1.66) | 0.17 | 15 | 12 | A/C vs C/C: 0.20 (0.06–0.71) | **0.0012** |
| | A/A or A/C | 73 | 11.3 | A/A or A/C vs C/C: 0.44 (0.19–1.30) | 0.08 | 41 | 11.3 | A/A or A/C vs C/C: 0.19 (0.06–0.63) | **0.0010** |
| | C/C | 7 | 5.2 | C/C vs A/A: 2.61 (0.86–8.56) | 0.074 | 6 | 5.1 | C/C vs A/A: 5.52 (1.40–17.4) | **0.0058** |

Composite of \textit{VHL} wildtype, mutated \textit{TP53}, and \textit{FLTI} C/C

| 0 | 54 | 14.5 | 1 vs 0: 1.78 (0.85–3.57) | 0.11 | 31 | 12 | 1 vs 0: 2.09 (0.82–4.99) | 0.12 |
| 1 | 20 | 9.1 | 2 or 3 vs 1: 3.83 (1.18–10.88) | **0.0052** | 11 | 9.1 | 2 or 3 vs 1: 3.80 (1.08–12.55) | **0.038** |
| 2 or 3 | 5 | 3.9 | 2 or 3 vs 0: 6.83 (2.17–18.26) | **0.0001** | 5 | 3.9 | 2 or 3 vs 0: 7.93 (2.31–24.64) | **0.0018** |

MOS, months; PFS, progression-free survival, HR, hazard ratio

https://doi.org/10.1371/journal.pone.0210415.t003
Fig 2. Progression-free survival on first line therapy. VHL (A, B), TP53 (C, D), FLT1 (E, F) variants, and composite of VHL wildtype, TP53 mutated, and FLT1 C/C (G, H) in all patients (left panel) and IMDC intermediate risk patients only (right panel).
levels of HIF result in increased expression of its downstream targets, including VEGF [9]. To date, studies of whether mutational status of \textit{VHL} is predictive of response to VEGF targeted therapy produced mixed results [10–13]. In a retrospective analysis of 123 patients treated with VEGF targeted therapy, loss of function mutations in \textit{VHL} were associated with improved response rates compared to wild-type \textit{VHL} (52% vs. 31%, p = 0.04) [10]. However, \textit{VHL} mutation/methylation status did not correlate with response rates or PFS in an analysis of 78 patients from a clinical trial evaluating pazopanib in mRCC [11].

\textit{TP53} encodes a well-known tumor suppressor protein and is a known prognostic biomarker for breast cancer, squamous cell carcinoma of the head and neck, and prostate cancer [14–16]. In clear cell RCC, genomic alterations in \textit{TP53} are a poor prognostic marker for overall survival (OS) [17]. A recent study also found increasing frequency of \textit{TP53} mutations after first-line VEGF TT, which suggests that \textit{TP53} may play a role in resistance [18]. \textit{FLT1} encodes the VEGFR and is the only validated, predictive, germline biomarker for response to VEGF TT in mRCC. An initial screen of 138 SNPs in patients treated with bevacizumab for either metastatic pancreatic or RCC found that only rs9582036 was predictive of PFS in mRCC [19]. They then studied \textit{FLT1} in patients with mRCC who were treated with first-line sunitinib and found the C/C variant was predictive of inferior RR, PFS, and OS [20, 21]. In our cohort, \textit{FLT1} C/C had a trend towards significance in the entire cohort and did predict inferior PFS in IMDC intermediate risk patients.

Recently, a few studies have reported the frequency of mutations in only mRCC, instead of all stages of RCC [12, 13, 22]. In our cohort, the incidence of \textit{VHL} mutations (75%, 71–83%) and \textit{TP53} mutations (6%, 8–11%) was similar to previously reported studies. More recognition has been given to the potential role of \textit{PBRM1}, \textit{BAP1}, \textit{SETD2}, and \textit{KDM5C} mutations in RCC. In a study of 111 patients treated with first-line sunitinib by Hsieh et al., they found that mutant \textit{KDM5C} was predictive of superior PFS compared to wild type (20.6 months vs. 8.3 months, p = 0.03) [13]. In a separate study of 95 patients treated with first-line VEGF TT, time-to-treatment-failure significantly differed by \textit{PBRM1} and \textit{BAP1} mutation status, no significant difference was seen with \textit{KDM5C} [22]. In our study, we did not see a significant difference in PFS associated with mutations in \textit{PBRM1}, \textit{BAP1}, or \textit{KDM5C}. To date, each study of first-line VEGF TT in mRCC, including ours, had a similar number of patients, was retrospective, and produced differing results. These findings suggest that larger and ideally prospective genetic biomarker studies are needed to validate the findings of these multiple small studies. Prospective clinical trials for novel treatments in mRCC need to include predictive biomarker studies that may help personalize first and second-line treatment for mRCC.

Table 4. Cox proportional hazard model for PFS and overall survival by IMDC risk criteria and sum of \textit{VHL} wildtype, \textit{TP53} mutated, and \textit{FLT1} C/C genotype (rs9582036).

| IMDC Risk Criteria | Progression-free Survival | Overall Survival |
|--------------------|---------------------------|-----------------|
|                    | Hazard ratio, 95% CI | Log-Rank | Hazard ratio, 95% CI | Log-Rank |
| Favorable           | ref                      | ref          | ref                      | ref |
| Intermediate        | 4.76 (1.41–29.68) | 0.0084     | 2.84 (0.83–17.80) | 0.10 |
| Poor                | 6.26 (1.70–40.41) | 0.0039     | 6.48 (1.76–41.79) | 0.0031 |
| Composite of \textit{VHL} wildtype, mutated \textit{TP53}, and \textit{FLT1} C/C |
| 0                   | 1 vs 0: 1.70 (0.81–3.42) | 0.15     | 1 vs 0: 2.36 (1.11–4.80) | 0.026 |
| 1                   | 2 or 3 vs 1: 3.76 (1.13–11.03) | 0.032  | 2 or 3 vs 1: 2.16 (0.48–7.21) | 0.28 |
| 2 or 3              | 2 or 3 vs 0: 6.40 (2.00–17.57) | 0.0033 | 2 or 3 vs 0: 5.11 (1.15–16.41) | 0.035 |

https://doi.org/10.1371/journal.pone.0210415.t004
Limitations of our study include its retrospective nature, limited cohort size with few IMDC favorable risk patients, and use of multiple VEGF targeted therapies. Unlike PFS and OS, the data on objective responses were not reliably collected in this retrospective analysis, and hence correlation with objective responses with the underlying GAs was not performed. While use of multiple VEGF TT may introduce heterogeneity into our outcomes, it also is more realistic for eventual use in the real world. In regards to IMDC risk group, few of our patients were IMDC favorable risk. While this was due to random selection, it would have been interesting to assess GAs and response to VEGF TT in more patients with IMDC favorable risk disease because favorable risk disease had improved response to VEGF TT in CheckMate 214. Future studies based on the results of our data could include: validation of the composite model while accounting for IMDC risk group, use of circulating tumor DNA NGS to assess if the composite model remains significant, and use of ctDNA to assess the frequency of the eight significant mutations in RCC.

**Materials and methods**

From an institutional database, patients diagnosed with metastatic clear cell predominant RCC, hereafter mRCC, between the years 2000–2013 who were treated with first-line VEGF TT and had primary tumor tissue available from nephrectomy for genomic analysis were included. A retrospective chart review was conducted to determine first-line treatment, duration of response, and IMDC risk criteria, and sites of metastases. For clarity, a predictive biomarker is one that predicts a differential response to specific treatments; whereas, a prognostic biomarker is one that yields information regarding a patient’s overall cancer outcome. Genomic DNA was extracted from macro-dissected FFPE sections of tumors ensuring >70% tumor burden. Gain/loss was evaluated by array-CGH (Agilent 4x180K) and differential (≥25/30%) copy number alterations (CNAs) were assessed using Nexus Copy Number Algorithm (BioDiscovery, Inc.). CNAs with >25% difference for weighted average frequency (WAF) and p<0.05 were considered significant [23]. Nucleotide variants were detected by massively parallel sequencing using a custom hybrid capture panel comprising 76 RCC-relevant mutated genes (covering coding exons and splice junctions) and 7 prognostic SNPs (S1 and S2 Tables), on a MiSeq (Illumina) to an average depth of ~300x. CLC Biomedical Genomic Workbench (Qiagen) was used for variant detection and Annovar was used for variant annotation. A schematic representing sequencing data analysis steps is provided in S1 Fig. Variants with a VAF (variant allele frequency) > 5% were considered further. The study was approved by the Institutional Review Board at the University of Utah (IRB# 00067518) and written consent was obtained from all patients.

**Statistical analysis**

The PFS was described using the Kaplan-Meier analysis and compared by genomic variants using the log-rank test. Cox proportional hazard models were created combining risk criteria and mutations status.

**Conclusion**

A composite model of tumor TP53 mutation, wild type VHL, and FLT1 C/C SNP is predictive of outcomes to treatment with VEGF TT in the first-line setting in a dose-dependent manner. Patients harboring tumor genomic markers predicting poor outcomes to VEGF targeted therapy may be candidates for agents targeting primarily non-VEGF pathways, such as checkpoint inhibitors, c-MET inhibitors, a combination of VEGF-TKI plus checkpoint inhibitors, or clinical trials. These results are hypothesis-generating and need external validation.
Supporting information

S1 Table. Selected genes included in panel for analysis.
(DOCX)

S2 Table. SNPs tested in analysis.
(DOCX)

S1 Fig. Schematic diagram depicting the bioinformatic flow for somatic variant identification.
(TIFF)

Author Contributions

Conceptualization: Neeraj Agarwal.

Data curation: Andrew W. Hahn, David M. Gill, Joseph Merriman.

Formal analysis: David D. Stenehjem, Erik B. Harrington, Neeraj Agarwal.

Investigation: Banumathy Gowrishankar, Venkata Thodima, Trang H. Au, Jane Houldsworth, Sumanta K. Pal.

Methodology: Daniel Albertson, Archana M. Agarwal, Venkata Thodima, Jane Houldsworth, Neeraj Agarwal.

Supervision: David D. Stenehjem, Benjamin L. Maughan, Sumanta K. Pal, Neeraj Agarwal.

Writing – original draft: Andrew W. Hahn.

Writing – review & editing: Andrew W. Hahn, Jane Houldsworth, Sumanta K. Pal, Neeraj Agarwal.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62(1):10–29. Epub 2012/01/13. https://doi.org/10.3322/caac.20138 PMID: 22237781.

2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. The New England journal of medicine. 1996; 335(12):865–75. Epub 1996/09/19. https://doi.org/10.1056/NEJM199609193351207 PMID: 8778606.

3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. The Urologic clinics of North America. 2003; 30(4):843–52. Epub 2003/12/19. PMID: 14680319.

4. McKay RR, Bosse D, Choueiri TK. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018;Jco2018790253. Epub 2018/10/30. https://doi.org/10.1200/jco.2018.79.0253 PMID: 30372392.

5. Motzer RJ, Powles T., Atkins M.B., et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology. 2018; 36(Suppl 6S):Abstr 578.

6. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(34):5794–9. Epub 2009/10/15. https://doi.org/10.1200/jco.2008.21.4809 PMID: 19826129.

7. Ko JJ, Xie W, Kroeger N, Lee JL, Knox BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. The Lancet Oncology. 2015; 16(3):293–300. Epub 2015/02/16. https://doi.org/10.1016/S1470-2045(14)71222-7 PMID: 25681967.
8. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43–9. Epub 2013/06/25. https://doi.org/10.1038/nature12222 PMID: 23792563; PubMed Central PMCID: PMCPMC3771322.

9. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet (London, England). 2009; 373(9669):1119–32. Epub 2009/03/10. https://doi.org/10.1016/s0140-6736(09)60229-4 PMID: 19269025.

10. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal carcinoma. The Journal of urology. 2008; 180(3):860–5; discussion 5–6. Epub 2008/07/19. https://doi.org/10.1016/j.juro.2008.05.015 PMID: 18635227.

11. Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(18):5218–26. Epub 2013/07/25. https://doi.org/10.1158/1078-0432.ccr-13-0491 PMID: 23881929; PubMed Central PMCID: PMCPmc4522695.

12. Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, et al. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus. 2016; 2(2):204–9. https://doi.org/10.1016/j.euf.2015.11.007 PMID: 28723536

13. Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European urology. 2017; 71(3):405–14. Epub 2016/10/19. https://doi.org/10.1016/j.euro.2016.10.007 PMID: 27751729.

14. Olivier M, Langoer A, Carrierie P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(4):1157–67. Epub 2006/02/21. https://doi.org/10.1158/1078-0432.ccr-05-1029 PMID: 16489069.

15. Poeta ML, Manola J, Goldwasser MA, Forstiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. The New England journal of medicine. 2007; 357(25):2552–61. Epub 2007/12/21. https://doi.org/10.1056/NEJMoa073770 PMID: 18094376; PubMed Central PMCID: PMCPmc2263014.

16. Che M, DeSilvio M, Pollack A, Grignon DJ, Venkatesan VM, Hanks GE, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. International journal of radiation oncology, biology, physics. 2007; 69(4):1117–23. Epub 2007/08/11. https://doi.org/10.1016/j.ijrobp.2007.04.070 PMID: 17689883; PubMed Central PMCID: PMCPmc2770594.

17. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell reports. 2018; 23(1):313–26.e5. Epub 2018/04/05. https://doi.org/10.1016/j.celrep.2018.03.075 PMID: 29616699.

18. Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European urology. 2017. Epub 2017/04/18. https://doi.org/10.1016/j.euro.2017.03.046 PMID: 28431327.

19. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. The Lancet Oncology. 2012; 13(7):724–33. Epub 2012/05/23. https://doi.org/10.1016/S1470-2045(12)70231-0 PMID: 22608783.

20. Beuselinc k B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib—a multicentric retrospective analysis. Acta oncologica (Stockholm, Sweden). 2014; 53(1):103–12. Epub 2013/02/21. https://doi.org/10.3109/0284186x.2013.770600 PMID: 23421954.

21. Beuselinc k B, Jean-Baptiste J, Schoffski P, Couchy G, Meiller C, Rolland F, et al. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. BJU international. 2016; 118(6):890–901. Epub 2016/07/16. https://doi.org/10.1111/bju.13585 PMID: 27417418.

22. Carlo Mi, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A, et al. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2017; 1:49–56. https://doi.org/10.3233/kca-160003 PMID: 30334004

23. Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, Buist DS, et al. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast cancer research and treatment. 2011; 127(1):297–308. Epub 2011/01/26. https://doi.org/10.1007/s10549-010-1297-x PMID: 21264507; PubMed Central PMCID: PMCPMC3224104.